Precision Immunotherapy to Improve Sepsis Outcomes

Does immunotherapy tailored to the type of immune dysregulation improve outcomes among patients with sepsis?In this multicenter randomized clinical trial of 276 patients, precision immunotherapy, which included the administration of anakinra for patients with macrophage activation–like syndrome and recombinant human interferon gamma for patients with sepsis-induced immunoparalysis, decreased the Sequential Organ Failure Assessment score by at least 1.4 points by day 9 in 35.1% of patients in the immunotherapy group vs 17.9% in the placebo group.A precision strategy of immunotherapy improved organ dysfunction at day 9 among patients with sepsis.

Corresponding Author: Evangelos J. Giamarellos-Bourboulis, MD, PhD, Fourth Department of Internal Medicine, ATTIKON University Hospital, One Rimini St, 12462 Athens, Greece (egiamarel@med.uoa.gr).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.